Chief Medical Officer · Tarsus Pharmaceuticals, Inc. (TARS)

Elizabeth Yeu-Lin

FY2024 is the first fiscal year CompBrief holds for Elizabeth Yeu-Lin as a named executive officer of Tarsus Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,104,857

Salary $78,182Stock awards $1,399,928Bonus $25,000

5th of 5 named executive officers at Tarsus Pharmaceuticals by FY2024 total.

5 named officers on file for Tarsus Pharmaceuticals, FY2024

Elizabeth Yeu-Lin’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 5 equity grants, each cited to its filing
  • TARS’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tarsus Pharmaceuticals’s whole pay program stands against its peers

  • Tarsus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TARS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A).

Free

Get Elizabeth Yeu-Lin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Elizabeth Yeu-Lin compensation by year

Tarsus Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Tarsus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$78,182
Bonus$25,000
Stock awards$1,399,928
Option awards$1,548,238
Non-equity incentive$0
Pension and deferred compensation$0
All other$53,509
Total$3,104,857

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tarsus Pharmaceuticals, Inc. DEF 14A filed April 28, 2025, accession 0001819790-25-000070, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Tarsus Pharmaceuticals, Inc. filed document, accession 0001819790-25-000070. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU27,278$1,510,383—
RSU3,350$185,490—
Option10,000—$26.25
Option5,000—$33.14
Option41,074—$46.21

Per the Outstanding Equity Awards at Fiscal Year-End table in Tarsus Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Tarsus Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Bobak AzamianPresident, Chief Executive Officer and Board Chairman$7,896,192
Jeffrey FarrowChief Financial Officer and Chief Strategy Officer$3,232,926
Seshadri NeervannanChief Operating Officer$3,194,689
Aziz MottiwalaChief Commercial Officer$3,138,862
Elizabeth Yeu-Lin · this pageChief Medical Officer$3,104,857

Board service

Tarsus Pharmaceuticals board · FY2021–FY2023
Director compensation in US dollars, as Tarsus Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2023$59,125$61,506$59,574—$180,205
FY2022$46,000$26,180$64,256—$136,436
FY2021$240,000$0$382,612—$622,612

Each year as the company reported it in Tarsus Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Tarsus Pharmaceuticals pays directors a $40,000 cash retainer. As stated in Tarsus Pharmaceuticals's FY2023 proxy.

Committees

Science and Technology (Chair)

The full Tarsus Pharmaceuticals compensation record

free company brief

This page is one person within Tarsus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tarsus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Elizabeth Yeu-Lin's compensation dossier · One-time report. No refunds.